<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03565146</url>
  </required_header>
  <id_info>
    <org_study_id>Focus-PiQo4 Pigmentation-17-01</org_study_id>
    <nct_id>NCT03565146</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of PiQo4 System for the Treatment of Pigmented Lesions</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of PiQo4 System for the Treatment of Pigmented Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Focus Medical, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Focus Medical, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of at least 25 healthy subjects at a single site, aged 21-70 years old with&#xD;
      congenital or acquired challenging/resistant, age/sun-related flat and benign facial&#xD;
      pigmentation with or without hand pigmentation who wish to improve their skin appearance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2018</start_date>
  <completion_date type="Actual">June 5, 2019</completion_date>
  <primary_completion_date type="Actual">June 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pigmentation Improvement Scale</measure>
    <time_frame>1 month follow up</time_frame>
    <description>Facial Pigmentation Improvement evaluated by the investigator at the 1 month follow up visit compared to baseline using a 5-point improvement scale where a score of between 0 and 4 will be assigned (0-No improvement; 1- Trace to mild improvement of some lesions; 2- Moderate response: some lesions lighter; 3- Good response: most lesions much lighter; 4 - excellent response: most or all lesions are much lighter or gone)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pigmentation Improvement Scale</measure>
    <time_frame>3 month follow up</time_frame>
    <description>Facial Pigmentation Improvement evaluated by the investigator at the 3 month follow up visit compared to baseline using a 5-point improvement scale where a score of between 0 and 4 will be assigned (0-No improvement; 1- Trace to mild improvement of some lesions; 2- Moderate response: some lesions lighter; 3- Good response: most lesions much lighter; 4 - excellent response: most or all lesions are much lighter or gone)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Pigmentation</condition>
  <arm_group>
    <arm_group_label>Pigmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of Pigmented Lesions Using PiQo4 Laser System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PiQo4 Laser System</intervention_name>
    <description>PiQo4 Laser System for treatment of pigmented lesions</description>
    <arm_group_label>Pigmentation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy Female or Male&#xD;
&#xD;
          2. Age= 21-70 (Adults)&#xD;
&#xD;
          3. Fitzpatrick skin phototype = I-V&#xD;
&#xD;
          4. Congenital or acquired benign pigmentation on face with optional pigmentation on hand.&#xD;
&#xD;
          5. Presence of at least 4 lesions of similar pigmentation intensity in the treatment&#xD;
             area, in diameters larger than 2 mm&#xD;
&#xD;
          6. Able to read, understand and provide written Informed Consent&#xD;
&#xD;
          7. Able and willing to comply with the treatment/follow-up schedule and requirements&#xD;
&#xD;
          8. Women of child-bearing potential are required to use a reliable method of birth&#xD;
             control (such as an intrauterine device, birth control pills, condom with spermicidal,&#xD;
             NuvaRing, partner with vasectomy, Implanon or other FDA-approved devices, or&#xD;
             abstinence) during the course of the study&#xD;
&#xD;
          9. Willing to have digital photographs taken of the treatment area&#xD;
&#xD;
         10. Willing to refrain from using any prescription or over the counter topical creams used&#xD;
             for the treatment of pigmentation (e.g., hydroquinone, retinoids, and/or&#xD;
             corticosteroids) in the treatment area during the study period.&#xD;
&#xD;
         11. Willing to protect from sun exposure and use an approved sunscreen of SPF 30 or higher&#xD;
             in the treatment area daily during the entire duration of the study, including the&#xD;
             follow-up period.&#xD;
&#xD;
         12. Agree not to undergo any other procedure(s) for the treatment of pigmentation or solar&#xD;
             lentigines during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of post inflammatory pigmentary disorders, particularly a tendency for hyper-&#xD;
             or hypo-pigmentation&#xD;
&#xD;
          2. Melasma&#xD;
&#xD;
          3. Excessive underlying vascular conditions (e.g. dense network of capillaries)&#xD;
&#xD;
          4. Pregnant, intending to become pregnant during the course of study, less than 3 months&#xD;
             postpartum or less than 3 months after completion of breastfeeding&#xD;
&#xD;
          5. Prior skin laser, light, or other energy device treatment in treated area within 6&#xD;
             months of initial treatment or during the course of the study&#xD;
&#xD;
          6. Prior ablative resurfacing procedure or face-lift in treated area with laser or other&#xD;
             devices within 12 months of initial treatment or during the course of the study&#xD;
&#xD;
          7. Prior treatment with medium-depth or deeper chemical peels or dermabrasion in treated&#xD;
             area within 3 months of initial treatment or during the course of the study&#xD;
&#xD;
          8. Prior use of any prescription or over the counter topical creams used for the&#xD;
             treatment of pigmentation (e.g., hydroquinone, retinoids, and/or corticosteroids) in&#xD;
             the treatment area within 3 months of initial treatment or during the course of the&#xD;
             study&#xD;
&#xD;
          9. Any other surgery in treated area within 9 months of initial treatment or during the&#xD;
             course of the study&#xD;
&#xD;
         10. Hypersensitive to light exposure or the use of photosensitive medication for which&#xD;
             light exposure is contraindicated&#xD;
&#xD;
         11. Multiple dysplastic nevi in area to be treated&#xD;
&#xD;
         12. Significant concurrent illness (e.g. uncontrolled diabetes) or any disease state that&#xD;
             in the opinion of the Investigator would interfere with the treatment or healing&#xD;
             process&#xD;
&#xD;
         13. Any dermal/epidermal damage or disorder, mainly vascular or textural lesions, in the&#xD;
             treatment area.&#xD;
&#xD;
         14. Any underlying tattoo in the treatment area.&#xD;
&#xD;
         15. Unable or unlikely to refrain from tanning, including the use of tanning booths,&#xD;
             during the course of the study&#xD;
&#xD;
         16. Participation in a study of another investigational device or drug involving the same&#xD;
             anatomical site within 3 months prior to enrollment or during this evaluation, or if&#xD;
             not involving the same anatomical site, as per the Investigator's discretion&#xD;
&#xD;
         17. History of keloid or any other type of hypertrophic scar formation or poor wound&#xD;
             healing&#xD;
&#xD;
         18. Signs and symptoms of hormonal disorders such as Melasma, as per the Investigator's&#xD;
             discretion.&#xD;
&#xD;
         19. Concurrent inflammatory skin conditions, open laceration, or abrasion of any sort on&#xD;
             area to be treated during the course of treatment&#xD;
&#xD;
         20. Active Herpes Simplex (perioral or facial) at the time of treatment or having&#xD;
             experienced more than three episodes of Herpes Simplex eruption within a year of study&#xD;
             enrollment&#xD;
&#xD;
         21. Having a bleeding disorder or taking anticoagulation medications, including daily use&#xD;
             of aspirin, in a manner which does not allow for a minimum 10 day washout period prior&#xD;
             to treatment (as per the discretion of the subject's primary care physician)&#xD;
&#xD;
         22. History of immunosuppression/immune deficiency disorders (including HIV infection or&#xD;
             AIDS) or the use of immunosuppressive medications&#xD;
&#xD;
         23. Having any form of active cancer at the time of enrollment and during the course of&#xD;
             the study or history of skin cancer on the face/hands&#xD;
&#xD;
         24. Pigmented lesions in the areas to be treated that are suspicious for pre-malignancy or&#xD;
             malignancy and/or are not deemed suitable for phototherapy, as per the Investigator's&#xD;
             discretion&#xD;
&#xD;
         25. Unable to understand or provide written Informed Consent (e.g. mental incompetence or&#xD;
             evidence of active substance abuse)&#xD;
&#xD;
         26. Any condition that, in the Investigator's opinion, would make it unsafe (for the&#xD;
             subject or for the study personnel) to treat the subject as part of this research&#xD;
             study&#xD;
&#xD;
         27. If undergoing punch biopsy, allergic to lidocaine or epinephrine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel P Friedmann</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westlake Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Westlake Dermatology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>December 25, 2019</last_update_submitted>
  <last_update_submitted_qc>December 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

